Establishment of a subsidiary for developing new cosmetics products using microalgae
First written in FY2021-Q2. 7 of 13 entries say "Advanced", first in FY2021-Q3. Latest entry: 2026-08-26.
No other company in this theme has enough history to compare yet.
- 2026-08-26DroppedOccurring FactSuggests it is closing out
「2026 年８月 26 日開催の取締役会において、同社の解散及び清算を決定いたしました。」
微細藻類事業を営んでいた株式会社アルヌールの解散・清算が決議され、同子会社を通じた事業の継続は終了する方向となった。 - FY2026AdvancedAnnual report
「In the microalgae business, which is a core business of this segment, the company made steady progress in research and development, including successfully achieving high-density cultivation of spirulina, which contains abundant nutritional and health-related components and is expected to have strong commercialization potential, and chinorimo, which is viewed as a promising future source of pharmaceutical and cosmetics ingredients.」
The microalgae business successfully achieved high-density cultivation of spirulina and chinorimo, progressing from the previous stage of capital investment and research and development to the cultivation of potential commercial products. - FY2024-Q3RestatedAnnual report
「The Group develops and sells “fucoxanthin,” a rare raw material derived from microalgae for use in beauty and health products.」
The company continues its efforts to develop and sell microalgae-derived fucoxanthin. - FY2024-Q2RestatedAnnual report
「The Group develops and sells “fucoxanthin,” a rare raw material derived from microalgae for use in beauty and health products.」
The company continues its efforts to develop and sell microalgae-derived fucoxanthin. - FY2024-Q1RestatedAnnual report
「The Group develops and sells “fucoxanthin,” a rare raw material derived from microalgae for use in beauty and health products.」
The company continues to report its efforts to develop and sell microalgae-derived fucoxanthin. - FY2023AdvancedAnnual report
「In the sustainable business, the company has received inquiries from multiple companies and begun new business relationships.」
In the sustainable business centered on microalgae, the company progressed from receiving inquiries from multiple companies to commencing new business relationships. Revenue from related businesses also amounted to ¥57.145 million. - FY2023-Q2RestatedAnnual report
「The Group develops and sells “fucoxanthin,” a rare raw material derived from microalgae for use in beauty and health products.」
The company continues to report its efforts to develop and sell microalgae-derived fucoxanthin. - FY2023-Q1AdvancedAnnual report
「The Group develops and sells “fucoxanthin,” a rare raw material derived from microalgae for use in beauty and health products.」
For microalgae-derived fucoxanthin, the scope of the initiative has progressed from research and development and capital investment to the development and sale of the raw material. - FY2022-Q2AdvancedAnnual report
「Property, plant and equipment amounted to ¥165.538 million, an increase of ¥55.192 million from the end of the previous consolidated fiscal year. This was mainly due to increases of ¥9.961 million in machinery and equipment and ¥42.553 million in construction in progress, resulting from investment in microalgae cultivation and extraction facilities, among other factors.」
Investment in microalgae cultivation and extraction facilities continued, increasing machinery and equipment by ¥9.961 million and construction in progress by ¥42.553 million. This indicates progress in facilities for developing products using microalgae-derived ingredients. - FY2022-Q1AdvancedAnnual report
「This was mainly due to an increase in cash and deposits and investment in microalgae cultivation and extraction facilities, among other factors.」
Investment was made in microalgae cultivation and extraction facilities, and construction in progress on the balance sheet amounted to ¥42.652 million. This indicates progress in facilities for developing products using microalgae-derived ingredients. - FY2021AdvancedAnnual report
「The Group is jointly developing skincare products with its consolidated subsidiary 株式会社アルヌール that contain fucoxanthin, a useful ingredient derived from microalgae, and plans to launch them as the fucoxanthin series from the second half of 2021 through 2022 and beyond.」
The company progressed to joint development with 株式会社アルヌール, which is responsible for culturing and extracting microalgae, and indicated plans to sell skincare products containing fucoxanthin from the second half of 2021 through 2022 and beyond. - FY2021-Q3AdvancedAnnual report
「On 30 November 2020, the company established 株式会社アルヌール as a new company, made it a consolidated subsidiary, and included it in the mail-order business.」
株式会社アルヌール, whose establishment had been planned in the previous quarter, was established and made a consolidated subsidiary on 30 November 2020. This represents organizational progress toward research and development of cosmetics and healthcare products using microalgae. - FY2021-Q2First statedAnnual report
「The company decided to establish a new company to expand the scale of its business by extracting useful ingredients from cultured microalgae, building a stable and scalable supply system, and developing new cosmetics products using these capabilities as a source of competitiveness.」
The company resolved on 29 October 2020 to establish a wholly owned subsidiary, scheduled for establishment on 30 November 2020, with capital of ¥30 million. Through the research and development, manufacturing and sale of biomedical and healthcare products centered on microalgae, it aims to develop new cosmetics products and build a stable, scalable raw-material supply system.